Quan V. Doan

2.7k total citations · 1 hit paper
33 papers, 2.0k citations indexed

About

Quan V. Doan is a scholar working on Radiology, Nuclear Medicine and Imaging, Ophthalmology and Oncology. According to data from OpenAlex, Quan V. Doan has authored 33 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Ophthalmology and 8 papers in Oncology. Recurrent topics in Quan V. Doan's work include Retinal Diseases and Treatments (8 papers), Retinal Imaging and Analysis (8 papers) and Neutropenia and Cancer Infections (5 papers). Quan V. Doan is often cited by papers focused on Retinal Diseases and Treatments (8 papers), Retinal Imaging and Analysis (8 papers) and Neutropenia and Cancer Infections (5 papers). Quan V. Doan collaborates with scholars based in United States, United Kingdom and Canada. Quan V. Doan's co-authors include Robert W. Dubois, Zhimei Liu, Mark D. Danese, Paul D. Blumenthal, Lionel Pinto, Michelle Gleeson, Chantal Dolan, Neil M. Bressler, Shoshana Colman and Rohit Varma and has published in prestigious journals such as Blood, PLoS ONE and Cancer.

In The Last Decade

Quan V. Doan

31 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of and Risk Factors for Diabetic Macular Edema in the United States

2014 298 citations Rohit Varma, Neil M. Bressler et al. profile →

Peers

Countries citing papers authored by Quan V. Doan

Since Specialization

Citations

This map shows the geographic impact of Quan V. Doan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quan V. Doan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quan V. Doan more than expected).

Fields of papers citing papers by Quan V. Doan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Quan V. Doan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quan V. Doan. The network helps show where Quan V. Doan may publish in the future.

Co-authorship network of co-authors of Quan V. Doan

This figure shows the co-authorship network connecting the top 25 collaborators of Quan V. Doan. A scholar is included among the top collaborators of Quan V. Doan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Quan V. Doan. Quan V. Doan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings	Journal of Emergency Medicine	Frank LoVecchio, Matthew W. McCarthy et al.	0
2	Place of care and costs associated with acute episodes and remission in schizophrenia	Journal of Managed Care & Specialty Pharmacy	Roger S. McIntyre, Quan V. Doan et al.	1
3	Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study	Dermatology and Therapy	Christiane Querfeld, Winnie W. Nelson et al.	7
4	Evaluation of the Path to Diagnosis and Time to Treatment in Patients with Light-Chain Amyloidosis Using the Komodo Claims Database	Blood	Quan V. Doan, Jennifer Evans et al.	0
5	Place of care and costs associated with acute episodes and remission in bipolar I disorder	Journal of Medical Economics	Roger S. McIntyre, Quan V. Doan et al.	3
6	PCN2 Recurrences Avoided and Life Years Saved Attributable to Trastuzumab Use in HER2+ Early and Metastatic Breast Cancer in the United States	Value in Health	Mark D. Danese, Quan V. Doan et al.	2
7	<p>Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema</p>	Clinical ophthalmology	Rohit Varma, Neil M. Bressler et al.	1
8	Visual Impairment and Blindness Avoided with Ranibizumab in Hispanic and Non-Hispanic Whites with Diabetic Macular Edema in the United States	Ophthalmology	Rohit Varma, Neil M. Bressler et al.	22
9	Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment	PLoS ONE	Paul Mitchell, Neil M. Bressler et al.	40
10	Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization	Archives of Ophthalmology	Neil M. Bressler, Quan V. Doan et al.	93
11	Relationship Between Disability and Health‐Related Quality of Life and Caregiver Burden in Patients With Upper Limb Poststroke Spasticity	PM&R	Quan V. Doan, Allison Brashear et al.	99
12	Estimating recurrences prevented from using trastuzumab in HER‐2/neu–positive adjuvant breast cancer in the United States	Cancer	Mark D. Danese, Deepa Lalla et al.	10
13	The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK	Applied Health Economics and Health Policy	Zhimei Liu, Quan V. Doan et al.	38
14	Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis	Journal of Managed Care Pharmacy	Lawrence Goldberg, Natalie C. Edwards et al.	86
15	Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population	Journal of Medical Economics	Quan V. Doan, Stephen M. Lange et al.	1
16	Economic burden of cardiovascular events and fractures among patients with end-stage renal disease	Current Medical Research and Opinion	Quan V. Doan, Michelle Gleeson et al.	30
17	A Systematic Review Evaluating Health-Related Quality of Life, Work Impairment, and Health-Care Costs and Utilization in Abnormal Uterine Bleeding	Value in Health	Zhimei Liu, Quan V. Doan et al.	266
18	Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials	Current Medical Research and Opinion	Lionel Pinto, Zhimei Liu et al.	134
19	Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis	Journal of Managed Care Pharmacy	Quan V. Doan, Chiun‐Fang Chiou et al.	64
20	PTH and the Risks for Hip, Vertebral, and Pelvic Fractures Among Patients on Dialysis	American Journal of Kidney Diseases	Mark D. Danese, John Kim et al.	235

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact